PT  - JOURNAL ARTICLE
AU  - NORIYUKI MASAKI
AU  - NATHANIEL F. WU
AU  - YUSUKE AOKI
AU  - JUN YAMAMOTO
AU  - JUN MIYAZAKI
AU  - ROBERT M. HOFFMAN
TI  - Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatinum and Eribulin
AID  - 10.21873/invivo.12605
DP  - 2021 Nov 01
TA  - In Vivo
PG  - 3107--3110
VI  - 35
IP  - 6
4099  - http://iv.iiarjournals.org/content/35/6/3107.short
4100  - http://iv.iiarjournals.org/content/35/6/3107.full
SO  - In Vivo2021 Nov 01; 35
AB  - Background/Aim: Primary osteosarcoma of the mammary gland is a very rare disease, accounting for less than 1% of all mammary malignancies. There is no established first-line treatment and the prognosis is poor compared to normal breast cancer. We previously established the first patient tumor-derived animal model of this disease, grown subcutaneously in nude mice. In the present study, we established a patient derived orthotopic xenograft (PDOX) model of osteosarcoma of the breast and investigated the efficacy of cisplatinum (CDDP) and eribulin (ERB). Materials and Methods: PDOX models of primary osteosarcoma of the breast were divided into 3 groups (5-6 mice per group): untreated control; CDDP treatment; ERB treatment. The tumor volume in the 3 groups was compared after 2 weeks. Results: There were significant differences between control and CDDP, and control and ERB (p=0.036, 0.046, respectively). However, there was no significant difference between CDDP and ERB (p=0.964). Conclusion: CDDP and ERB are candidates for first-line clinical therapy of primary osteosarcoma of the breast.